ANEB Key Statistics, Chart & Performance
The current stock price of ANEB is 2.36 USD. In the past month the price decreased by -10.61%. In the past year, price increased by 63.32%.
ANEB Latest News, Press Relases and Analysis
ANEB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.11 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.78 | 494.73B | ||
| MRK | MERCK & CO. INC. | 11.56 | 252.74B | ||
| PFE | PFIZER INC | 7.9 | 143.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.12B | ||
| ZTS | ZOETIS INC | 20.07 | 56.08B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.71 | 23.03B | ||
| VTRS | VIATRIS INC | 4.59 | 12.32B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.56 | 11.24B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.66 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.51B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.37B |
Related stock screener links
About ANEB
Company Profile
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Company Info
ANEBULO PHARMACEUTICALS INC
C/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107
Lakeway TEXAS US
CEO: Daniel Schneeberger
Employees: 2
Phone: 17372035270
ANEBULO PHARMACEUTICALS INC / ANEB FAQ
Can you describe the business of ANEBULO PHARMACEUTICALS INC?
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
What is the stock price of ANEBULO PHARMACEUTICALS INC today?
The current stock price of ANEB is 2.36 USD. The price increased by 0.85% in the last trading session.
Does ANEBULO PHARMACEUTICALS INC pay dividends?
ANEB does not pay a dividend.
What is the ChartMill rating of ANEBULO PHARMACEUTICALS INC stock?
ANEB has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ANEBULO PHARMACEUTICALS INC (ANEB) stock?
6 analysts have analysed ANEB and the average price target is 8.16 USD. This implies a price increase of 245.76% is expected in the next year compared to the current price of 2.36.
Should I buy ANEB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ANEB.
ANEB Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ANEB. When comparing the yearly performance of all stocks, ANEB is one of the better performing stocks in the market, outperforming 90.3% of all stocks.
ANEB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANEB. ANEB has a great financial health rating, but its profitability evaluates not so good.
ANEB Financial Highlights
Over the last trailing twelve months ANEB reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 23.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.86% | ||
| ROE | -72.78% | ||
| Debt/Equity | 0 |
ANEB Forecast & Estimates
6 analysts have analysed ANEB and the average price target is 8.16 USD. This implies a price increase of 245.76% is expected in the next year compared to the current price of 2.36.